Ethris Signs Strategic Collaboration with Thermo Fisher Scientific to Provide Access to mRNA Technology Platforms
The collaboration brings together Ethris' comprehensive mRNA technology platforms, including its proprietary Stabilized Non-Immunogenic mRNA (SNIM ® RNA), minimal UTR and mRNA manufacturing technologies with Thermo Fisher's industry-leading end-to-end GMP-compliant manufacturing capabilities. Broadening global access to Ethris' comprehensive suite of mRNA technology platforms, the partners will facilitate the ability of biopharmaceutical developers to rapidly advance candidate mRNA medicines from research to clinical proof-of-concept.
'Thermo Fisher Scientific has a long-standing track record of supporting the development of advanced therapies,' said Dr. Carsten Rudolph, CEO of Ethris. 'By combining our clinically validated mRNA platforms with Thermo Fisher's manufacturing expertise, we are creating a powerful offering for biopharma partners. This collaboration addresses the increasing demand for scalable, high-quality mRNA technologies and enables us to serve a broader set of collaborators worldwide.'
The collaboration will also support the continued optimization of Ethris' platform technologies, which have already demonstrated positive pharmacodynamic effects, safety and targeted engagement in Phase 1 topline data of its lead candidate, ETH47. Designed for local administration via nasal spray to address the upstream trigger of asthma exacerbations, ETH47 showed dose-dependent, localized production of the encoded protein, interferon lambda at the site of administration, with no systemic bioavailability. The study confirmed that ETH47 activated downstream signaling, demonstrating the expressed protein's functional activity. Given its non-immunogenic nature, SNIM® RNAs can be administered repeatedly, leading to sustained production of therapeutically active proteins within the human body. Eligible for multiple routes of administration, the technology can replace or augment missing or non-functional proteins that cause a disease, introduce new proteins to modulate the course of the disease or its symptoms and be used to develop vaccines.
'Thermo Fisher is committed to supporting the rapid translation of breakthrough therapies into clinical application,' said Ben Castro, Vice President and General Manager, Large Molecule, Drug Substance, Thermo Fisher Scientific. 'By partnering with Ethris, we are expanding our services to include cutting-edge mRNA manufacturing, empowering our customers to bring life-changing treatments to patients faster and more efficiently.'
Ethris' SNIM® RNA platform sets new standards for mRNA therapeutics by enabling safe, efficacious and stable drug products as well as scalable manufacturing, expanding the potential of mRNA medicines.
About Ethris
Ethris, a clinical-stage biotechnology company, has paved a new path from genes to therapeutic proteins, using its proprietary RNA and lipidoid nanoparticle technology platform to discover, design and develop innovative therapies. With more than a decade as an mRNA pioneer, Ethris is a global leader in delivering stabilized mRNAs directly to the respiratory system via optimised formulation and nebulisation technologies. The company is rapidly advancing its mRNA pipeline of immuno-modulation, protein replacement therapies, and differentiated vaccines, with the ultimate goal of improving patients' lives.
For more information, visit www.ethris.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
35 minutes ago
- Business Wire
Bonerge Unveils StanYouth® CR3: A Revolutionary Anti-Aging Complex Merging TCM Wisdom and Cellular Science
NEW YORK--(BUSINESS WIRE)--Bonerge has unveiled its revolutionary anti-aging Product, StanYouth® CR3, a patented formula that bridges Traditional Chinese Medicine (TCM) philosophy with cutting-edge cellular science. Inspired by TCM's "Senolytic-Repair-Chi" theory, this synergistic complex targets aging at the cellular level, offering a multi-dimensional solution to combat senescence. Rooted in the TCM principle of "treating disease before it arises," StanYouth® CR3 operates through a three-stage mechanism mirroring "Senolytic-Repair-Chi." Its core ingredients—Fisetin (FIS), Urolithin A (UA), and L-Ergothioneine (EGT)—work in harmony to address aging at its source. Fisetin: The Senolytic Purifier As a natural flavonoid with superior cell membrane penetration, Fisetin selectively eliminates senescent cells—dysfunctional cells that linger and secrete pro-inflammatory senescence-associated secretory phenotypes (SASP), accelerating tissue aging. It not only clears existing senescent cells but also reduces new ones, cutting inflammatory factor production at the source to purify the cellular environment [1,2]. Urolithin A: The Homeostasis Restorer Cellular aging thrives on disrupted metabolic and circadian rhythms, which worsen inflammation and weaken clock gene function. Urolithin A repairs this balance by regulating core clock genes (e.g., CLOCK, PER2) critical for gut metabolism and boosting the expression amplitude of BMAL1 in senescent cells, restoring their circadian rhythms and metabolic homeostasis [3,4]. L-Ergothioneine: The Defense Enhancer Environmental stress and metabolism generate reactive oxygen/nitrogen species (ROS/RNS) that damage DNA and deplete vitality. L-Ergothioneine, via its unique OCTN-1 transporter, accumulates in high-oxidative-stress areas like mitochondria and nuclei, neutralizing free radicals in real time. It also upregulates endogenous antioxidant enzymes, strengthening cellular resilience and nourishing vital energy ("Chi")[5,6]. Synergistic Power: A Closed-Loop Mechanism Together, they form a "Senolytic-Repair-Chi" cycle. Fisetin clears senescent burdens, creating a healthy foundation; Urolithin A restores rhythms and metabolism; L-Ergothioneine fortifies defenses, preventing further damage—each amplifying the others' effects. Cellular Experiments Validate Superiority Tests on human dermal fibroblasts revealed striking results: StanYouth® CR3 cleared up to 80% of senescent cells, doubling Fisetin's solo performance. It suppressed senescence markers p16 and p21 to near-normal levels, outperforming single ingredients. Critically, it reduced pro-inflammatory IL-6, IL-8, and fibrosis-driving IL-11 to baseline, blocking the "senescence-inflammation-fibrosis" cycle. It also inhibited UVB-induced ROS and boosted cell migration —key for repair—far better than individual components. Clinical Trial Confirms Efficacy A 56-day human trial showed StanYouth® CR3 outperformed standalone L-Ergothioneine: skin firmness (F4) rose 16.3%, under-eye wrinkles fell 11.28%, brightness (L*) increased 1.4%, and fairness (ITA) improved 6.10%, skin barrier repair (TEWL reduction) reached 18.18%. "StanYouth® CR3 is more than an anti-aging formula— it's a bridge between ancient TCM wisdom and modern cellular science," noted a Bonerge product manager. By translating the holistic "Senolytic-Repair-Chi" principle into a precise, synergistic cellular strategy, it delivers proven efficacy from laboratory to real-world application. As Bonerge continues to explore its potential beyond skin health, StanYouth® CR3 marks a new era in evidence-based anti-aging, where tradition and innovation converge to redefine vitality. References [1] Kento Takaya, et al. Biogerontology. 2024 Feb;25(1):161-175. [2] Li Zhang, Xiang Tong, et al. Front Pharmacol. 2020 Dec 14:11:553690. [3] Yao Du, Xinyue Chen et al. Nutrients 2024, 16, 2263. [4] Rassul Kuatov, Jiro Takano et 2024 Dec 25;17(1):20. [5] Hui-Min Liu, Wei Tang, et al. Molecules. 2023 Feb 8;28(4):1648. [6] Yasaaswini Apparoo, Chia Wei Phan, et al. Exp Gerontol. 2022 Dec:170:111982.
Business Wire
3 hours ago
- Business Wire
Global Active Cyber Insurance Leader Coalition Launches in France
PARIS--(BUSINESS WIRE)-- Coalition, the world's first Active Insurance provider designed to help prevent digital risk before it strikes, today announced the launch of its Active Cyber Insurance in France through its subsidiary, Coalition Insurance Solutions GmbH. French companies with revenues of up to €1 billion can now access innovative cyber risk management and cyber insurance coverage on a primary basis. Capacity is provided by Allianz Commercial via Allianz Global Corporate & Specialty SE (AGCS) in a multi-year agreement. 'Coalition's Active Insurance combines comprehensive cyber insurance with internal technical cybersecurity knowledge, technologies, and services for a completely integrated approach to risk,' commented Tine Simonsen, Coalition's Head of Insurance, Continental Europe. 'As global cyber threats grow, French businesses—small businesses especially—need an experienced and innovative insurance provider that not only helps mitigate financial losses, but also equips them with the cybersecurity tools necessary to better understand their risks, strengthen their defenses, and prevent future attacks.' Coalition's integrated approach to cyber risk management combines some of the most comprehensive coverage available on the market with cybersecurity solutions and services. Through Active Insurance, policyholders can identify, mitigate, and respond to emerging cyber threats before they escalate into full-blown attacks. The company delivers end-to-end protection backed by in-house technical expertise, cutting-edge technologies, and expert support services focused exclusively on cybersecurity. Through Coalition's proprietary cyber risk management platform, Coalition Control®, insured companies benefit from a complete assessment of their exposure and risk, and receive alerts about vulnerabilities and cyber threats as they emerge. Businesses can also access security services, including employee security awareness training and managed detection and response (MDR). In the event of an incident, Coalition's claims and incident response teams are available 24/7. To support the launch of its French operations, Coalition also announced the appointment of Benjamin Barès as its Head of Business Development for France. He joins with more than 20 years of industry experience, most recently as Director of Direct Sales and Partnerships at Hiscox Assurances France. 'I'm thrilled to be joining Coalition, a trusted insurance provider for over 100,000 organizations and a partner to over 65,000 brokers worldwide,' added Barès. 'Our ambition in France—as around the globe—is to establish long-lasting relationships with brokers and agencies, supported by extensive training materials and broker-specific resources, as well as a streamlined quoting process that enables brokers to obtain quotes within minutes via our online Broker Platform.' Barès will be supported by a team that includes Frédéric Gatte as Director of Underwriting with strong cyber expertise gained from his recent positions at Onda and Diot Siaci, and Production Underwriter Tom Paparella, who transfers from Coalition's U.S. team. The company plans to expand its workforce in several French cities. To learn about further open positions, visit: Brokers can start quoting now by submitting requests directly to Coalition's expert underwriting team at help@ For more information about Coalition and Active Insurance, please visit: About Coalition Coalition is the world's first Active Insurance provider designed to help prevent digital risk before it strikes. By combining comprehensive insurance coverage and cybersecurity tools, Coalition helps businesses manage and mitigate potential cyberattacks. Leveraging its relationships with leading global insurers and capacity providers, including Coalition Insurance Company, Coalition offers Active Insurance products to businesses in the United States, the United Kingdom, Canada, Australia, Germany, Denmark, Sweden, and France. Policyholders can receive automated cyber alerts and access expert advice and global third-party risk management tools through Coalition's cyber risk management platform, Coalition Control®. Insurance cover is issued by Coalition Insurance Solutions GmbH, German insurance agent (HRB 133708) supervised by IHK Frankfurt am Main, Börsenplatz 4, 60313 Frankfurt am Main, having a French branch registered with the RCS of Paris under number 940 794 753 to act as European insurance intermediary under ORIAS number D-JEO5-724A4-24 ('CIS FR'), cooperating in the French market with Allianz Global Corporate & Specialty SE, a company organized and existing under the laws of Germany, registered at the Munich Commercial Register under the No HRB 208312, headquartered Königinstrasse 28, 80802 Munich (Germany), acting through its French Branch, registered at the Commercial Register ('RCS') of Nanterre under the No 487 424 608, whose head office is located 1 Cours Michelet – CS 30051 - 92076 Paris La Défense Cedex. This information with regard to the cyber insurance products provided herein is of a general nature only and does not take into account any person's particular circumstances. All descriptions of coverage are subject to the terms, conditions, and exclusions of the individual policy. Before making a decision (or advising your client), please refer to the relevant applicable policy or contact your broker. CIS FR may receive remuneration from an insurer. See imprint and disclaimers
Business Wire
3 hours ago
- Business Wire
UK University Clearing Chaos: Students on Hold for More Than Three Hours - Unless the University Used 8x8
LONDON--(BUSINESS WIRE)--As A-level results dropped last Thursday, students across England, Wales, and Northern Ireland scrambled to secure university places through Clearing — and many were forced to wait more than three hours on hold to do so, according to new data from 8x8, Inc. (NASDAQ: EGHT), the industry's most integrated customer experience (CX) platform provider. In the UK, Clearing is a process where students who do not have a university place or have changed their mind on which course they wish to attend call universities directly after exam results are published to see if they can claim one of the remaining spots. With more than 22,000 undergraduate courses still open, phone lines across the UK were quickly overwhelmed. And while Clearing technically runs until October, the first few days are critical – with places awarded on a first-come, first-served basis. But for students calling 8x8-powered universities, the experience looked very different. Average wait times dropped to just six seconds, and most calls were resolved end-to-end in under eight minutes. After the first weekend of Clearing since the exam results dropped, data shared with 8x8 from a number of university bodies revealed: Across the UK, some applicants were on hold for more than three hours before reaching the relevant university employees. 80% of call volume took place on the Thursday of exam results being received. 8x8-supported universities recorded wait times of less than eight seconds for a call to be answered - while some (non-8x8 supported) universities had average wait times of above 16 minutes. At 8x8-supported universities, total call handling times were around eight minutes - and in some cases under two minutes. Removing stress from the process 'Clearing is high-stakes for students and universities alike as every second on hold adds stress and the risk of losing a place or funding,' said Maxine Eunson, Head of Public Sector and Universities at 8x8, Inc. 'I hear that, at non-8x8 supported universities, average handling time on Clearing has been more than ten minutes and it's great our tools are helping universities be quicker and better than that as we help them move from chaos to clarity.' 8x8 and Education More information about how 8x8 helps universities and other educational institutions can be found on the company's customer success page. About 8x8 Inc. 8x8, Inc. (NASDAQ: EGHT) connects people and organizations through seamless communication on the industry's most integrated platform for Customer Experience – combining Contact Center, Unified Communication, and CPaaS solutions. The 8x8® Platform for CX integrates AI at every level to enable personalized customer journeys, drive operational excellence and insights, and facilitate team collaboration. 8x8 helps customer experience and IT leaders become the heartbeat of their organizations, empowering them to unlock the potential of every interaction. For additional information, visit or follow 8x8 on LinkedIn, X, and Facebook.
